Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New MRI-Guided brain zaps aim to ease anxiety in days

NCT ID NCT07640945

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a faster version of brain stimulation for generalized anxiety disorder. Instead of weeks of treatment, participants receive five sessions per day for five days. The stimulation is guided by each person's MRI scan to target a specific brain area linked to anxiety. The trial will include 75 adults aged 18-65 to see if this approach safely reduces anxiety symptoms more quickly than standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
continuous theta burst stimulation (cTBS) via transcranial magnetic stimulation (TMS) device
What this could lead to
If it works, this could provide a faster treatment option for generalized anxiety disorder, reducing symptoms in days instead of weeks.
What could go wrong
This is an early-stage trial with only 75 people, so results may not apply to everyone. The treatment is intensive (5 sessions per day for 5 days) and may cause discomfort or side effects like headache.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Outpatients or inpatients at the Second Xiangya Hospital who are confirmed by two experienced psychiatrists to meet the International Classification of Diseases 11th Revision (ICD-11) diagnostic criteria for generalized anxiety disorder. * Aged 18 to 65 years, regardless of gender. * Right-handed. * Junior high school education or above, with the ability to provide informed consent and complete cognitive assessments. * Able to receive anti-anxiety treatment during the follow-up period according to the instructions of outpatient or inpatient physicians. * Hamilton Anxiety Rating Scale (HAMA) score ≥14 and Patient Health Questionnaire-15 (PHQ-15) score ≥5. Exclusion Criteria: * Presence of psychotic symptoms. * Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, current psychiatric symptoms, or post-traumatic stress disorder based on SCID-5 assessment, either currently or within the past year. * Organic brain disease or severe somatic diseases, such as thyroid disease, lupus, diabetes, lung disease, liver disease, kidney disease, infection, or major trauma. * Intracranial implants. * Clinically significant sensory impairments that cannot be corrected, such as color blindness or hearing impairment. * Pregnant or breastfeeding women. * Positive urine drug screen. * Abnormal thyroid function tests. * Personal history of epilepsy or family history of epilepsy. * Receipt of physical therapy within the past six months, such as repetitive transcranial magnetic stimulation or electroconvulsive therapy. * Suspected or confirmed history of alcohol or drug dependence. * Use of anticoagulants, such as heparin or warfarin, corticosteroids, or thyroid disease treatments within the past three months. * Current use of psychoactive medications. * Receipt of neurocognitive assessments similar to those used in this study within the past 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Generalized anxiety disorder (GAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.